This article is about what is the current net worth of Martin Shkreli. Martin Shkreli is a name that many people associate with greed, controversy and fraud. The former pharmaceutical executive, who earned the nickname "Pharma Bro" for his notorious price hike of a life-saving drug, has been in and out of legal troubles for years.
What is the Current Net Worth of Martin Shkreli?
Shkreli's net worth has fluctuated significantly over time, depending on his business ventures, legal battles and financial penalties. According to his own legal team, the majority of his wealth came from his stake in Turing Pharmaceuticals, the company he founded in 2015 and that acquired the rights to Daraprim, an antiparasitic drug used to treat HIV patients. Shkreli raised the price of Daraprim from $13.50 to $750 per pill, sparking public outrage and criticism from politicians, celebrities and medical experts.
At the peak of his fame (or infamy), Shkreli was estimated to have a net worth of $70 million in 2015 . However, his fortune soon took a hit as he faced multiple lawsuits and criminal charges for securities fraud and conspiracy related to his previous hedge fund and biotech companies, Retrophin and MSMB Capital Management. He was convicted on two counts of securities fraud and one count of conspiracy in 2017 and sentenced to seven years in prison and up to $7.4 million in fines .
In addition, Shkreli was ordered to forfeit $5 million from his ETrade account and $2.36 million worth of other assets, including a Pablo Picasso painting and an unreleased Wu-Tang Clan album that he bought for $2 million in 2015 . He also faced a civil antitrust lawsuit for abusing his monopoly power over Daraprim and was banned from working in the pharmaceutical industry for life and ordered to return $64.6 million in profits he earned from price-gouging Daraprim .
As of 2023. Shkreli's net worth is estimated to be around $25-$27 million, a significant drop from his previous peak. However, some sources claim that he still has a share in Turing Pharmaceuticals, which was renamed Vyera Pharmaceuticals in 2018. and that his stake could be worth as much as $70 million . Shkreli also launched a new software company called Gödel Systems in 2016. which aims to develop artificial intelligence solutions for finance and biotech industries.
How Did Martin Shkreli Make His Net Worth?
One of his most notable investments was Retrophin, a biotech company that focused on developing treatments for rare diseases. He founded the company in 2011 and became its CEO in 2012. He used Retrophin's funds to acquire the rights to several drugs, including Daraprim, a drug used to treat toxoplasmosis, a parasitic infection that can be fatal for people with weakened immune systems. In 2015. he raised the price of Daraprim from $13.50 to $750 per pill, claiming that the increase was necessary to fund research and development. However, many critics accused him of price gouging and exploiting vulnerable patients.
Shkreli's actions attracted the attention of the US government, which accused him of securities fraud and wire fraud in 2015. The charges stemmed from his alleged mismanagement of his hedge funds and Retrophin, where he was accused of using the company's assets to pay off his personal debts and investors. He was convicted on three counts in 2017 and sentenced to seven years in prison in 2018. He also had to forfeit $7.4 million in assets, including a rare Wu-Tang Clan album that he had bought for $2 million.
Shkreli is currently serving his sentence at a federal prison in Pennsylvania. He has maintained his innocence and appealed his conviction, but his appeal was denied in 2019. He has also continued to be active on social media and online platforms, where he has shared his opinions on various topics, including politics, music, and science. He has also claimed to be working on a cure for COVID-19 from prison.
Bottom Line
In this article, we have discussed what is the current net worth of Martin Shkreli. Shkreli's net worth has fluctuated over the years, depending on his legal troubles and the value of his assets.
